Clinical Trial

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

Study acronym: PROVIDE
Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2026-10-31 2026-07-21
minor Completion pushed: 2026-06-30 -> 2026-10-31 2026-07-21
Trial Details
NCT Number NCT06143514
Lead Sponsor TG Therapeutics, Inc.
Conditions Relapsing Multiple Sclerosis
Enrollment 16 participants
Start Date 2024-03-26
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20